… Outcome measures at week 14 for vedolizumab therapy in patients with (A) Crohn’s disease
and (B) ulcerative colitis. *P value less than .005 when comparing week 6 and week 14 …

… of vedolizumab in patients with inflammatory bowel disease (… and safety of vedolizumab
maintenance therapy (at week 54) … -to-severe active UC and CD who failed anti-TNF therapy. …

… track closely with luminal disease. In this case series, vedolizumab therapy was effective for
… , but did not provide sustained benefit for the treatment of PG in CD. Notably, most of these …

… In conclusion, the final analysis of GEMINI LTS comprehensively demonstrates that
vedolizumab therapy has a safety and tolerability profile suitable for long-term treatment of patients …

… We identified six eligible Crohn’s disease and seven eligible ulcerative colitis trials that …
per disease cohort to infliximab or vedolizumab. In the Crohn’s disease and ulcerative colitis …

… Vedolizumab is a humanized monoclonal … intestinal inflammation. This study aimed to
evaluate the efficacy and safety of vedolizumab in the treatment of inflammatory bowel disease. …

… of vedolizumab therapy at a dose of 300 mg every 4 weeks in patients who did not have
a sufficient response to vedolizumab therapy and de-escalation of vedolizumab therapy to a …

… Vedolizumab, a humanized monoclonal antibody against α4β7 … ulcerative colitis (UC) and
Crohn’s disease (CD). We investigated the time course of clinical response to vedolizumab in …

… vedolizumab therapy. Among adult UC subjects demonstrating clinical response from
vedolizumab … 54 weeks of therapy, 80% of subjects remained on vedolizumab therapy. Outcomes …

… -induced clinical remission in patients with CD may not be apparent before treatment week
… that vedolizumab treatment of UC and CD should be discontinued if a therapeutic benefit is …